x

Search for a networks

* (*) mandatory field

A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy - coordination

  • Type of network : Multinational clinical trials
  • Funded by an IRDiRC member
  • Geographic coverage : Global
  • Funding body(ies) : PTC THERAPEUTICS, INC. 
  • Sponsor : Barth
  • Website
  • Coordinator of multinational clinical trial

  • Dr Jay BARTH
  • PTC Therapeutics Inc.
  • 100 Corporate Court
  • SOUTH PLAINFIELD NJ 07080-2449
  • UNITED STATES
  • More information
  • Phone  : 190 82 22 70 00
  • Fax  : 190 82 22 72 31
  • Website
  • Contact secretary  :
Last update: May 2017

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.